BioXData Companies

Investments within BioXData

Wing exists to help you build a multi-billion dollar independent company. We invest in visionary founders who aren’t just solving the unsolvable, but are tackling the right challenges for our future.
Wing

BioXData Companies

Select one...
Select one...
Filter
Filter
Select one...
Select one...
Select one...
set filters
See all Companies
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Company
Intro
Initial Investment
Status
Asimov
Wing Companies
Series A
Private
Asimov
Programming living biological systems
Series A
(
2020
)
Private
Private
Private
Private
Early science R&D was trial-and-error based. Asimov brings engineering to biology to bring us one step closer to programmable medicines.
Alec Nielsen
CEO and co-founder
Christopher Voigt
Co-founder
Douglas Densmore
Co-founder
Raja Srinivas
Co-founder
Cartography
Wing Companies
Pre-seed
Private
Cartography
Antigen atlas for precision therapies
Pre-seed
(
2020
)
Private
Private
Private
Private
Drugs are only as good as what they target, and the field has been using the same targets randomly discovered through academic work. Cartography is the first company to systematically profile healthy and diseased tissue cell-by-cell to discover robust targets that lead to better, safer drugs.
Ansuman Satpathy
Co-founder
Howard Chang
Co-founder
Kevin Parker
CEO and co-founder
Clear Labs
Wing Companies
Series A
Private
Clear Labs
Automated pathogen genomic sequencing/epidemiology
Series A
(
)
Private
Private
Private
Private
Clear Labs's automation, lower cost, and productization makes pathogen sequencing far more accessible, tranforming time to intervention with data relevant to many diseases and medical conditions.
Sasan Amini
CEO and co-founder
Mahni Ghorashi
Co-founder
DeepSight
Wing Companies
Pre-seed
Default
DeepSight
Diagnostic medical imaging
Pre-seed
(
2020
)
Default
Default
Default
Default
Deepsight will significantly improve ultrasound performance making this safe, non-invasive technology far more usable.
Lan Yang
Co-founder
Nader Sadrzadeh
CEO and Co-founder
Glyphic Biotechnologies
Wing Companies
Pre-seed
Private
Glyphic Biotechnologies
Accurate protein sequencing
Pre-seed
(
)
Private
Private
Private
Private
Proteomics lags genomics in speed and accuracy of sequencing. Glyphic's approach will solve this at scale unlocking a massively valuable bio dataset.
Daniel Estandian
Co-founder
Joshua Yang
CEO and co-founder
Matterworks
Wing Companies
Seed
Private
Matterworks
AI metabolomics platform
Seed
(
2020
)
Private
Private
Private
Private
Today it's impossible to get real-time metabolic insights on biology, an incredibly important dataset for the life sciences. Matterworks' ML approach enables real-time insights into cellular biology.
Mimoun Cadosch Delmar
CEO
Mytos
Wing Companies
Seed
Private
Mytos
Automated cell manufacturing
Seed
(
)
Private
Private
Private
Private
Growing cells is the first step in creating drugs that work, yet today it's an artisinal, error-prone process run by over-qualified scientist. Mytos fully automates manufacture of any human cell types.
Ali Afshar
CEO
Ignacio Willats
Co-founder
PrognomIQ
Wing Companies
Pre-seed
Private
PrognomIQ
Early disease detection and treatment
Pre-seed
(
)
Private
Private
Private
Private
Despite genomics advancements there is still a tremendous unmet need for higher sensitivity with high specificity in early cancer detection. PrognomIQ generates multiomic data at scale in their next-gen approach to early cancer detection.
Philip Ma
Seer
Wing Companies
Series B
IPO
Seer
Broad/deep proteomics platform
Series B
(
2019
)
IPO
IPO
IPO
IPO
Learn more about Seer and why we invested in their vision. At Wing we’re committed to helping founders like Omid Farokhzad do their best work.
Omid Farokhzad
CEO and co-founder
Unnatural Products
Wing Companies
Seed
Private
Unnatural Products
AI macrocycle discovery platform
Seed
(
2020
)
Private
Private
Private
Private
70% of drug targets are too complex for small molecules and beyond the reach of biologics. Unnatural Product's ML platform engineers macrocycles to drug today's undruggable.
Cameron Pye
Joshua Schwochert
Vevo Therapeutics
Wing Companies
Pre-seed
Private
Vevo Therapeutics
In vivo data for drugs
Pre-seed
(
2022
)
Private
Private
Private
Private
Drug discovery is only as powerful as the data that fuels it, and today that data is generated out of context from how disease occurs in living organisms while also failing to account for the diverse mosaic of genetic backgrounds across patients. Vevo is the first platform to make in vivo data generation scalable bringing this important context earlier in drug development to create better drugs.
Hani Goodarzi
Co-founder
Johnny Yu
Co-founder
Nima Alidoust
CEO and co-founder
Wing Logo
Thanks for signing up!
Form error, try again.